May. 27 at 1:59 PM
Two 100% losers from my portfolio.
$BXRXQ (Baudax Bio) shareholders are marginally more likely to recover some of their investment compared to
$AVCTQ shareholders due to the more recent bankruptcy filing (February 2024 vs. January 2023), which may allow for an ongoing reorganization process, and the potential value of Baudax Bio’s pharmaceutical pipeline (e.g., TI-168, BX1000). However, recovery prospects for both are extremely low, as common shareholders in Chapter 11 bankruptcies typically receive little to no distribution. Any recovery for BXRXQ or AVCTQ shareholders would likely be minimal (e.g., cents on the dollar) and depend on rare circumstances, such as a successful reorganization or unexpected asset sale surplus. Investors should approach both stocks with caution, as their OTC trading status reflects high risk and speculative value.